VIVUS, Inc. (NASDAQ:VVUS)

CAPS Rating: 2 out of 5

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.

Results 1 - 20 of 82 : 1 2 3 4 5 Next »

Recs

0
Member Avatar OklaBoston (67.73) Submitted: 10/11/2014 4:27:24 PM : Outperform Start Price: $3.22 VVUS Score: +3.24

Recent good quarter and ranking officer open market buying last year indicate good possibility of short-covering in coming months.

And with a short ratio of 32.77% the covering should will provide a sizable boost to the stock, which is trading at less than half it's 600 day high.

Doesn't that sound like serious upside potential?

Recs

0
Member Avatar s2dbaker (76.49) Submitted: 10/16/2013 11:04:44 PM : Outperform Start Price: $9.66 VVUS Score: -78.41

A pill that help prevent type II diabetes and promotes weight loss. This is a winner.

Recs

0
Member Avatar manirg (76.56) Submitted: 6/14/2013 12:48:32 PM : Outperform Start Price: $14.24 VVUS Score: -95.18

obesity drug will catch on

Recs

0
Member Avatar VictorLeung (< 20) Submitted: 4/26/2013 1:16:09 PM : Outperform Start Price: $12.84 VVUS Score: -96.85

It seems that their Stendra(ED Drug) is better than Viagra. Stendra is going to market.

Recs

0
Member Avatar LIFESAVA1 (< 20) Submitted: 4/19/2013 5:31:47 PM : Outperform Start Price: $11.88 VVUS Score: -96.51

VVUS HAS A GREAT WEIGHT LOSS PRODUCT

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 3/3/2013 9:37:23 PM : Underperform Start Price: $10.24 VVUS Score: +95.24

Qsymia was a total flop at initial release, and that is without any competition. As soon as Belviq hits the shelves, Qsymia sales will drop substantially.

Recs

0
Member Avatar SmartEquity (34.49) Submitted: 1/21/2013 9:09:52 AM : Outperform Start Price: $13.34 VVUS Score: -105.93

I believe the scrips will pick up as distribution is improved. The obesity patients will choose a riskier Qsymia over a safer less effective Belviq.

Recs

0
Member Avatar clymerjones (59.77) Submitted: 10/17/2012 11:09:13 AM : Outperform Start Price: $22.25 VVUS Score: -118.20

Strong product/development initiatives will out class the S&P

Recs

0
Member Avatar greatspeculator (38.30) Submitted: 10/3/2012 2:00:40 AM : Outperform Start Price: $18.51 VVUS Score: -116.17

Good fundamentals. Speculation.

Recs

0
Member Avatar dausama (87.04) Submitted: 9/23/2012 9:54:13 AM : Underperform Start Price: $20.62 VVUS Score: +117.81

no EU approval

Recs

0
Member Avatar donodonuts (70.09) Submitted: 8/9/2012 7:16:43 AM : Outperform Start Price: $21.77 VVUS Score: -123.33

Sold it at like 8, oops. But their stuff hasn't hit the market yet, I'd like to think it will go up more when they have actual sales.

Recs

0
Member Avatar rick3000 (< 20) Submitted: 7/17/2012 5:16:39 PM : Underperform Start Price: $30.33 VVUS Score: +132.08

Inflated by ARNA approval, will crash to actual value if rejected or with restrictive label. Management has a black eye from handling of FDA announcement.

Recs

0
Member Avatar ravens9111 (53.81) Submitted: 7/16/2012 11:26:58 AM : Underperform Start Price: $27.97 VVUS Score: +131.56

Betting against this stock's FDA decision tomorrow. Price is most likely already priced in for approval. I expect a sell the news event even if approval is granted. However, if rejected, this stock will go to low teens to high single digits.

Recs

0
Member Avatar HIGHG33K (90.13) Submitted: 7/13/2012 8:39:49 PM : Outperform Start Price: $27.55 VVUS Score: -131.58

FDA approval is inevitable.

Recs

0
Member Avatar natemwilson (46.20) Submitted: 6/28/2012 12:08:47 PM : Underperform Start Price: $28.54 VVUS Score: +135.90

Too many adverse side effects to be approved.

Recs

0
Member Avatar nobleartjim (< 20) Submitted: 6/23/2012 9:48:19 AM : Outperform Start Price: $26.34 VVUS Score: -134.71

Recent developing products now undergoing FDA tests appear favorable

Recs

0
Member Avatar BACnumber1 (< 20) Submitted: 6/12/2012 12:13:40 PM : Outperform Start Price: $24.75 VVUS Score: -133.77

Fine stock, but I'm way bigger on ARNA

Recs

0
Member Avatar GoodTrader1 (< 20) Submitted: 6/6/2012 4:38:42 PM : Outperform Start Price: $24.32 VVUS Score: -132.07

high relative strenght

Recs

0
Member Avatar Wanker01 (52.05) Submitted: 5/1/2012 1:07:03 PM : Outperform Start Price: $24.59 VVUS Score: -123.96

Old people want to do it to

Recs

0
Member Avatar donscaccia (< 20) Submitted: 4/26/2012 10:47:24 AM : Outperform Start Price: $24.37 VVUS Score: -125.97

lets go vvus

Results 1 - 20 of 82 : 1 2 3 4 5 Next »

Featured Broker Partners


Advertisement